title: The effects of systemic and intratumoral interleukin-12 treatment in C6 rat glioma model.
abstract: OBJECTIVE
  Cytokine based immunotherapy has long been an exciting field for many investigators aiming to provide an effective alternative treatment modality for glioma management. Among these cytokines, interleukin-12 (IL-72) plays a crucial role in mediating inflammatory and antitumoral activity on the host defence. We have investigated the therapeutic role of systemic and local delivery of IL-12 in C6 rat glioma model and compared these two modalities.
  
  
  METHODS
  The donor C6 glioma cells were injected stereotactically to 32 Wistar rats and right frontal tumor formation was established in all subjects. The rats were evenly divided into four groups as intratumoral (i.t.) control group (Group IA), intraperitoneal (i.p.) control group (Group IB), i.t. treatment group (Group II) and i.p. treatment group (Group III). Magnetic resonance imaging were performed to 72 rats (three from each group) on the seventh post-inoculation day. Recombinant mouse IL-12 (rmIL-12) was administered via i.t. (0.1 microg 5 microl/day/rat) and i.p. (0.1 microg 20 microl/day/rat) routes to treatment groups between days 9 and 11 following tumor inoculation, for 3 consecutive days. The rats which were unresponsive to the external stimuli, unable to feed themselves or having severe neurological impairment were decapitated and the specimens were histopathologically examined.
  
  
  RESULTS
  The subjects of Group ILL (i.p.) showed a statistically significant prolongation in survival time (mean = 39 days) when compared to the control group (mean = 31.7 days) (p = 0.035) and Group II (i.t.) (mean = 24.5 days) (p = 0.005). Histopathologic examination of Group III revealed markedly increased intratumoral and peritumoral lymphocyte infiltration compared with the other groups.
  
  
  CONCLUSIONS
  This study demonstrated that systemic administration of IL- 12 in C6 glioma model in rats prolongs the survival, probably by stimulating the cellular immunity leading to lymphocytic infiltration.
authors.affiliation: Department of Neurosurgery and Department of Pathology, Cerrahpasa Medical Faculty, Istanbul. dronurulu@gmail.com
authors.forename: Necmettin
authors.initials: N
authors.lastname: Tanriover
authors.forename: Mustafa O
authors.initials: MO
authors.lastname: Ulu
authors.forename: Galip Z
authors.initials: GZ
authors.lastname: Sanus
authors.forename: Ayhan
authors.initials: A
authors.lastname: Bilir
authors.forename: Resit
authors.initials: R
authors.lastname: Canbeyli
authors.forename: Buge
authors.initials: B
authors.lastname: Oz
authors.forename: Ziya
authors.initials: Z
authors.lastname: Akar
authors.forename: Cengiz
authors.initials: C
authors.lastname: Kuday
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D045744:Cell Line, Tumor / Q000473:pathology; D004195:Disease Models, Animal; D004333:Drug Administration Routes; D005910:Glioma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018664:Interleukin-12 / Q000627:therapeutic use*; D009368:Neoplasm Transplantation / Q000379:methods; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
chemical_list: D000276:Adjuvants, Immunologic; D018664:Interleukin-12